Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial

OBJECTIVE: To assess the efficacy and safety of ultra-low dose 0.005% estriol vaginal gel in women with breast cancer receiving nonsteroidal aromatase inhibitors (NSAIs) and experiencing treatment-related vulvovaginal symptoms and signs. METHODS: Women with hormone receptor-positive early breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirschberg, Angelica Lindén, Sánchez-Rovira, Pedro, Presa-Lorite, Jesús, Campos-Delgado, Miriam, Gil-Gil, Miguel, Lidbrink, Elisabet, Suárez-Almarza, Javier, Nieto-Magro, Concepción
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott-Raven Publishers 2020
Materias:
Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188038/
https://www.ncbi.nlm.nih.gov/pubmed/32049923
http://dx.doi.org/10.1097/GME.0000000000001497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188038/
https://www.ncbi.nlm.nih.gov/pubmed/32049923
http://dx.doi.org/10.1097/GME.0000000000001497

Ejemplares similares